Independent review of E2100: A phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer

Robert Gray, Suman Bhattacharya, Christopher Bowden, Kathy Miller, Robert L. Comis

Research output: Contribution to journalArticle

229 Citations (Scopus)

Abstract

Purpose: E2100, an open-label, randomized, phase III trial conducted by the Eastern Cooperative Oncology Group (ECOG), demonstrated a significant improvement in progression-free survival (PFS) and overall response rate (ORR) with paclitaxel plus bevacizumab compared with paclitaxel alone as initial chemotherapy for patients with HER2-negative metastatic breast cancer. Methods: An independent, blinded review of radiologic and clinical data was performed, assessing progression and response according to Response Evaluation Criteria in Solid Tumors. In addition, ECOG's investigator assessments were reanalyzed using the same methods applied to the independent review. The primary end point was PFS as assessed by an independent review facility (IRF). Results: The addition of bevacizumab to paclitaxel resulted in a statistically significant improvement in PFS using both the IRF and investigator assessments. Hazard ratios for PFS (0.48, 95% CI, 0.385 to 0.607; P

Original languageEnglish (US)
Pages (from-to)4966-4972
Number of pages7
JournalJournal of Clinical Oncology
Volume27
Issue number30
DOIs
StatePublished - Oct 20 2009

Fingerprint

Paclitaxel
Disease-Free Survival
Breast Neoplasms
Research Personnel
Drug Therapy
Bevacizumab

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Independent review of E2100 : A phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. / Gray, Robert; Bhattacharya, Suman; Bowden, Christopher; Miller, Kathy; Comis, Robert L.

In: Journal of Clinical Oncology, Vol. 27, No. 30, 20.10.2009, p. 4966-4972.

Research output: Contribution to journalArticle

Gray, Robert ; Bhattacharya, Suman ; Bowden, Christopher ; Miller, Kathy ; Comis, Robert L. / Independent review of E2100 : A phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. In: Journal of Clinical Oncology. 2009 ; Vol. 27, No. 30. pp. 4966-4972.
@article{3000843527104748afed8aa3f4023432,
title = "Independent review of E2100: A phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer",
abstract = "Purpose: E2100, an open-label, randomized, phase III trial conducted by the Eastern Cooperative Oncology Group (ECOG), demonstrated a significant improvement in progression-free survival (PFS) and overall response rate (ORR) with paclitaxel plus bevacizumab compared with paclitaxel alone as initial chemotherapy for patients with HER2-negative metastatic breast cancer. Methods: An independent, blinded review of radiologic and clinical data was performed, assessing progression and response according to Response Evaluation Criteria in Solid Tumors. In addition, ECOG's investigator assessments were reanalyzed using the same methods applied to the independent review. The primary end point was PFS as assessed by an independent review facility (IRF). Results: The addition of bevacizumab to paclitaxel resulted in a statistically significant improvement in PFS using both the IRF and investigator assessments. Hazard ratios for PFS (0.48, 95{\%} CI, 0.385 to 0.607; P",
author = "Robert Gray and Suman Bhattacharya and Christopher Bowden and Kathy Miller and Comis, {Robert L.}",
year = "2009",
month = "10",
day = "20",
doi = "10.1200/JCO.2008.21.6630",
language = "English (US)",
volume = "27",
pages = "4966--4972",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "30",

}

TY - JOUR

T1 - Independent review of E2100

T2 - A phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer

AU - Gray, Robert

AU - Bhattacharya, Suman

AU - Bowden, Christopher

AU - Miller, Kathy

AU - Comis, Robert L.

PY - 2009/10/20

Y1 - 2009/10/20

N2 - Purpose: E2100, an open-label, randomized, phase III trial conducted by the Eastern Cooperative Oncology Group (ECOG), demonstrated a significant improvement in progression-free survival (PFS) and overall response rate (ORR) with paclitaxel plus bevacizumab compared with paclitaxel alone as initial chemotherapy for patients with HER2-negative metastatic breast cancer. Methods: An independent, blinded review of radiologic and clinical data was performed, assessing progression and response according to Response Evaluation Criteria in Solid Tumors. In addition, ECOG's investigator assessments were reanalyzed using the same methods applied to the independent review. The primary end point was PFS as assessed by an independent review facility (IRF). Results: The addition of bevacizumab to paclitaxel resulted in a statistically significant improvement in PFS using both the IRF and investigator assessments. Hazard ratios for PFS (0.48, 95% CI, 0.385 to 0.607; P

AB - Purpose: E2100, an open-label, randomized, phase III trial conducted by the Eastern Cooperative Oncology Group (ECOG), demonstrated a significant improvement in progression-free survival (PFS) and overall response rate (ORR) with paclitaxel plus bevacizumab compared with paclitaxel alone as initial chemotherapy for patients with HER2-negative metastatic breast cancer. Methods: An independent, blinded review of radiologic and clinical data was performed, assessing progression and response according to Response Evaluation Criteria in Solid Tumors. In addition, ECOG's investigator assessments were reanalyzed using the same methods applied to the independent review. The primary end point was PFS as assessed by an independent review facility (IRF). Results: The addition of bevacizumab to paclitaxel resulted in a statistically significant improvement in PFS using both the IRF and investigator assessments. Hazard ratios for PFS (0.48, 95% CI, 0.385 to 0.607; P

UR - http://www.scopus.com/inward/record.url?scp=73349120007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73349120007&partnerID=8YFLogxK

U2 - 10.1200/JCO.2008.21.6630

DO - 10.1200/JCO.2008.21.6630

M3 - Article

C2 - 19720913

AN - SCOPUS:73349120007

VL - 27

SP - 4966

EP - 4972

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 30

ER -